CLAIMS

1. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of inherited thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

2. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

3. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of cerebral infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

4. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of myocardial infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

5. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of ischemic reperfusion injury in a mammal in need thereof by subcutaneous

administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

6. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of deep vein thrombosis in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

7. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of treating sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises 20-4000 activity units per kilogram.

8. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of inherited thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for inherited TTP as measured in activity units per kilogram.

9. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of acquired thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for acquired TTP as measured in activity units per kilogram.

10. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of cerebral infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for cerebral infarction as measured in activity units per kilogram.

11. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of myocardial infarction in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for myocardial infarction as measured in activity units per kilogram.

12. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of ischemic reperfusion injury in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for ischemic reperfusion injury as measured in activity units per kilogram.

13. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of deep vein thrombosis in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for deep vein thrombosis as measured in activity units per kilogram.

14. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 and at least one of a pharmaceutically acceptable salt, sugar, sugar alcohol, non-ionic surfactant, and buffering agent in the manufacture of a medicament for the treatment of sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration, wherein the therapeutically effective amount of ADAMTS13 comprises at least 120-300% of the amount of a standard intravenous dose for sepsis-related disseminated intravascular coagulation as measured in activity units per kilogram.

15. The use of claim 8, wherein the specific indication is inherited TTP and the standard intravenous dose is 10-80 activity units per kilogram.

16. The use of claim 9, wherein the specific indication is acquired TTP and the standard intravenous dose is 20-1000 activity units per kilogram.

17. The use of claim 11 or 12, wherein the specific indication is myocardial infarction and/or ischemic reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram.

18. The use of claim 10 or 12, wherein the specific indication is cerebral infarction and/or ischemic reperfusion injury and the standard intravenous dose is 20-2000 activity units per kilogram.

19. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for the treatment of acute inflammation, chronic inflammation, *plasmodium falciparum* malaria, snake bites, frostbite, burns, hemolytic uremic syndrome, arterial thrombosis, coronary heart disease, or atherosclerosis in a mammal in need thereof by subcutaneous administration.

20. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for reducing a neurological manifestation and/or reducing fatigue associated with thrombotic thrombocytopenic purpura (TTP) in a mammal in need thereof by subcutaneous administration.

21. The use of claim 20, wherein the neurological manifestation is an alteration of mental status, stroke, seizures, hemiplegia, paresthesias, visual disturbance, and/or aphasia.

22. Use of a therapeutically effective amount of a composition comprising isolated ADAMTS13 in the manufacture of a medicament for treating thrombotic thrombocytopenic purpura (TTP), cerebral infarction, myocardial infarction. ischemic/reperfusion injury, deep vein thrombosis, or sepsis-related disseminated intravascular coagulation in a mammal in need thereof by subcutaneous administration.

23. The use of any one of claims 20-22, wherein the TTP is inherited TTP.

24. The use of any one of claims 20-22, wherein the TTP is acquired TTP.

25. The use of any one of claims 1-24, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose.

26. The use of any one of claims 1-25, wherein the bioavailability of the ADAMTS13 after subcutaneous administration is at least 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80% as compared to intravenous administration normalized for the same dose.

27. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-100 activity units per kilogram.

28. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-160 activity units per kilogram.

29. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-2000 activity units per kilogram.

30. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 20-4000 activity units per kilogram.

31. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 40-2000 activity units per kilogram.

32. The use of any one of claims 1-26, wherein the therapeutically effective amount comprises at least 40-4000 activity units per kilogram.

33. The use of any one of claims 1-32, wherein the ADAMTS13 is to be administered in a single bolus injection, monthly, every two weeks, weekly, twice a week, daily, every 12 hours, every 8 hours, every six hours, every four hours, or every two hours.

34. The use of any one of claims 1-33, wherein the ADAMTS13 is recombinant.

35. The use of any one of claims 1-33, wherein the ADAMTS13 is plasma derived.

36. The use of any one of claims 1-35, wherein the mammal is a human.

37. The use of any one of claims 1-36, wherein the composition is a stable aqueous solution ready for administration.

38. The use of any one of claims 1-37, wherein the composition is lyophilized.

39. The use of any one of claims 1-38, wherein the composition is reconstituted with a pharmaceutically acceptable vehicle suitable for injection prior to administration.